Skip to main content
. 2020 Sep 9;11:583311. doi: 10.3389/fphar.2020.583311

Figure 5.

Figure 5

Forest plot of the risk of intracranial bleeding of NOACs versus VKAs in elderly atrial fibrillation patients ≥75 years old. Api 5/2.5, apixaban 5 mg (standard dose) and 2.5 mg (reduced dose); CI, confidence interval; Dabi 150, dabigatran 150 mg (standard dose); Dabi 110, dabigatran 110 mg (reduced dose); Edo 60/30, edoxaban 60 mg (standard dose) and 30 mg (reduced dose); HR, hazard ratio; ICH, intracranial bleeding; NOAC, non-vitamin K antagonist oral anticoagulant; RCT, randomized controlled trial (post hoc analysis); RE model, random effects model; Riva, rivaroxaban; Riva 20/15, rivaroxaban 20 mg (standard dose) and 15 mg (reduced dose); VKA, vitamin K antagonist.